abstract: OBJECTIVE: This study evaluates the cost-effectiveness of @entity3 extended release (ER) as an add-on therapy to acetylcholinesterase inhibitor (AChEI) [combination therapy] for treatment of @entity0 with moderate-to-severe @entity1 ( @entity1 ) from both a healthcare payer and a societal perspective over 3 years when compared to AChEI monotherapy in the US. METHODS: A phase III trial evaluated the efficacy and safety of @entity3 ER for treatment of @entity1 @entity0 taking an AChEI. The analysis assessed the long-term costs and health outcomes using an individual @entity0 simulation in which @entity1 progression is modeled in terms of cognition, behavior, and functioning changes. Input parameters are based on @entity0 -level trial data, published literature, and publicly available data sources. Changes in anti- @entity2 medication use are incorporated based on a published retrospective cohort study. Costs include drug acquisition and monitoring, total @entity1 -related medical care, and informal care associated with caregiver time. Incremental cost-utility ratio (ICUR), life years, care time for caregiver, time in community and institution, time on anti-psychotics, time by disease severity, and time without severe symptoms are reported. Costs and health outcomes are discounted at 3% per annum. RESULTS: Considering a societal perspective over 3 years, this analysis shows that @entity3 ER combined with an AChEI provides better clinical outcomes and lower costs than AChEI monotherapy. Discounted average savings were estimated at  18,355 and  20,947 per @entity0 and quality-adjusted life-years (QALYs) increased by an average of 0.12 and 0.13 from a societal and healthcare payer perspective, respectively. @entity0 on combination therapy spent an average of 4 months longer living at home and spend less time in moderate-severe and severe stages of the disease. CONCLUSION: Combination therapy for @entity0 with moderate-to-severe @entity1 is a cost-effective treatment compared to AChEI monotherapy in the US.

title: Cost-utility analysis of @entity3 extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the XXXX in the US.

answer: @entity1


abstract: OBJECTIVE: This study evaluates the cost-effectiveness of @entity3 extended release (ER) as an add-on therapy to acetylcholinesterase inhibitor (AChEI) [combination therapy] for treatment of @entity0 with moderate-to-severe @entity1 ( @entity1 ) from both a healthcare payer and a societal perspective over 3 years when compared to AChEI monotherapy in the US. METHODS: A phase III trial evaluated the efficacy and safety of @entity3 ER for treatment of @entity1 @entity0 taking an AChEI. The analysis assessed the long-term costs and health outcomes using an individual @entity0 simulation in which @entity1 progression is modeled in terms of cognition, behavior, and functioning changes. Input parameters are based on @entity0 -level trial data, published literature, and publicly available data sources. Changes in anti- @entity2 medication use are incorporated based on a published retrospective cohort study. Costs include drug acquisition and monitoring, total @entity1 -related medical care, and informal care associated with caregiver time. Incremental cost-utility ratio (ICUR), life years, care time for caregiver, time in community and institution, time on anti-psychotics, time by disease severity, and time without severe symptoms are reported. Costs and health outcomes are discounted at 3% per annum. RESULTS: Considering a societal perspective over 3 years, this analysis shows that @entity3 ER combined with an AChEI provides better clinical outcomes and lower costs than AChEI monotherapy. Discounted average savings were estimated at  18,355 and  20,947 per @entity0 and quality-adjusted life-years (QALYs) increased by an average of 0.12 and 0.13 from a societal and healthcare payer perspective, respectively. @entity0 on combination therapy spent an average of 4 months longer living at home and spend less time in moderate-severe and severe stages of the disease. CONCLUSION: Combination therapy for @entity0 with moderate-to-severe @entity1 is a cost-effective treatment compared to AChEI monotherapy in the US.

title: Cost-utility analysis of XXXX extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the @entity1 in the US.

answer: @entity3


abstract: Importance: The Standard of Care vs Corticosteroid for @entity2 (SCORE) Study showed that intravitreal @entity3 (IVTA) is effective at reducing macular @entity1 and improving visual acuity in @entity0 with @entity2 . Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provides guidance for clinical decision making and management of @entity0 treated with IVTA. Objective: To investigate the incidence, risk factors, and time course of IOP elevation in @entity0 in the SCORE Study. Design, Setting, and @entity0 : Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites. Six hundred eighty-two @entity0 with macular @entity1 secondary to @entity2 were enrolled in the study. The SCORE Study enrollment period ran from November 4, 2004, to February 29, 2008, with @entity0 follow-up ending February 28, 2009. Interventions: Study @entity0 were randomized to standard of care, 1 mg of IVTA, or 4 mg of IVTA therapy and followed up for a mean (SD) of 24.7 (10.3) months. Main Outcomes and Measures: Intraocular pressure elevation greater than 10 mm Hg from baseline. Results: Kaplan-Meier incidences of IOP elevation greater than 10 mm Hg from baseline at 36 months were 0.02 (95% CI, 0.01-0.06), 0.09 (95% CI, 0.05-0.14), and 0.45 (95% CI, 0.38-0.53) in the standard of care, 1-mg IVTA, and 4-mg IVTA groups, respectively. The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P    <=   .001 for main outcome measure). Younger age, 4-mg IVTA vs 1-mg IVTA treatment, and higher baseline IOP were found to confer greater risk for IOP-related events (P   <   .05 for all). The median number of days from time of first injection to IOP elevation greater than 10 mm Hg from baseline was 34.0 and 52.5 days in @entity0 treated with 1-mg and 4-mg IVTA, respectively. Conclusions and Relevance: Intravitreal @entity3 injection therapy, in particular the 4-mg dose, is associated with an increased risk for IOP elevation. The risk factors for an IOP-related event include higher treatment dose, younger age, and higher baseline IOP. Intraocular pressure-related events may take several months from the time of first IVTA injection to occur. Clinicians should be mindful of these risk factors when assessing the risks and benefits of IVTA therapy and also of the need for long-term follow-up of @entity0 at risk for this complication. Trial Registration: clinicaltrials.gov Identifier: NCT00105027.

title: Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal XXXX Injection for Macular @entity1 Secondary to @entity2 : SCORE Study Report 15.

answer: @entity3


abstract: Importance: The Standard of Care vs Corticosteroid for @entity2 (SCORE) Study showed that intravitreal @entity3 (IVTA) is effective at reducing macular @entity1 and improving visual acuity in @entity0 with @entity2 . Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provides guidance for clinical decision making and management of @entity0 treated with IVTA. Objective: To investigate the incidence, risk factors, and time course of IOP elevation in @entity0 in the SCORE Study. Design, Setting, and @entity0 : Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites. Six hundred eighty-two @entity0 with macular @entity1 secondary to @entity2 were enrolled in the study. The SCORE Study enrollment period ran from November 4, 2004, to February 29, 2008, with @entity0 follow-up ending February 28, 2009. Interventions: Study @entity0 were randomized to standard of care, 1 mg of IVTA, or 4 mg of IVTA therapy and followed up for a mean (SD) of 24.7 (10.3) months. Main Outcomes and Measures: Intraocular pressure elevation greater than 10 mm Hg from baseline. Results: Kaplan-Meier incidences of IOP elevation greater than 10 mm Hg from baseline at 36 months were 0.02 (95% CI, 0.01-0.06), 0.09 (95% CI, 0.05-0.14), and 0.45 (95% CI, 0.38-0.53) in the standard of care, 1-mg IVTA, and 4-mg IVTA groups, respectively. The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P    <=   .001 for main outcome measure). Younger age, 4-mg IVTA vs 1-mg IVTA treatment, and higher baseline IOP were found to confer greater risk for IOP-related events (P   <   .05 for all). The median number of days from time of first injection to IOP elevation greater than 10 mm Hg from baseline was 34.0 and 52.5 days in @entity0 treated with 1-mg and 4-mg IVTA, respectively. Conclusions and Relevance: Intravitreal @entity3 injection therapy, in particular the 4-mg dose, is associated with an increased risk for IOP elevation. The risk factors for an IOP-related event include higher treatment dose, younger age, and higher baseline IOP. Intraocular pressure-related events may take several months from the time of first IVTA injection to occur. Clinicians should be mindful of these risk factors when assessing the risks and benefits of IVTA therapy and also of the need for long-term follow-up of @entity0 at risk for this complication. Trial Registration: clinicaltrials.gov Identifier: NCT00105027.

title: Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal @entity3 Injection for Macular @entity1 Secondary to XXXX : SCORE Study Report 15.

answer: @entity2


abstract: Importance: The Standard of Care vs Corticosteroid for @entity2 (SCORE) Study showed that intravitreal @entity3 (IVTA) is effective at reducing macular @entity1 and improving visual acuity in @entity0 with @entity2 . Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provides guidance for clinical decision making and management of @entity0 treated with IVTA. Objective: To investigate the incidence, risk factors, and time course of IOP elevation in @entity0 in the SCORE Study. Design, Setting, and @entity0 : Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites. Six hundred eighty-two @entity0 with macular @entity1 secondary to @entity2 were enrolled in the study. The SCORE Study enrollment period ran from November 4, 2004, to February 29, 2008, with @entity0 follow-up ending February 28, 2009. Interventions: Study @entity0 were randomized to standard of care, 1 mg of IVTA, or 4 mg of IVTA therapy and followed up for a mean (SD) of 24.7 (10.3) months. Main Outcomes and Measures: Intraocular pressure elevation greater than 10 mm Hg from baseline. Results: Kaplan-Meier incidences of IOP elevation greater than 10 mm Hg from baseline at 36 months were 0.02 (95% CI, 0.01-0.06), 0.09 (95% CI, 0.05-0.14), and 0.45 (95% CI, 0.38-0.53) in the standard of care, 1-mg IVTA, and 4-mg IVTA groups, respectively. The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P    <=   .001 for main outcome measure). Younger age, 4-mg IVTA vs 1-mg IVTA treatment, and higher baseline IOP were found to confer greater risk for IOP-related events (P   <   .05 for all). The median number of days from time of first injection to IOP elevation greater than 10 mm Hg from baseline was 34.0 and 52.5 days in @entity0 treated with 1-mg and 4-mg IVTA, respectively. Conclusions and Relevance: Intravitreal @entity3 injection therapy, in particular the 4-mg dose, is associated with an increased risk for IOP elevation. The risk factors for an IOP-related event include higher treatment dose, younger age, and higher baseline IOP. Intraocular pressure-related events may take several months from the time of first IVTA injection to occur. Clinicians should be mindful of these risk factors when assessing the risks and benefits of IVTA therapy and also of the need for long-term follow-up of @entity0 at risk for this complication. Trial Registration: clinicaltrials.gov Identifier: NCT00105027.

title: Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal @entity3 Injection for Macular XXXX Secondary to @entity2 : SCORE Study Report 15.

answer: @entity1


abstract: OBJECTIVE: Recent studies have proposed that the temporal discrimination threshold (TDT), the shortest detectable time period between two stimuli, is a possible endophenotype for @entity3 ( @entity3 ). @entity0 with @entity3 , the third most common @entity2 , and their first-degree relatives have been shown to have abnormal @entity1 . For this reason it is important to fully characterize each @entity0 's data. To date the TDT has only been reported as a single value. APPROACH: Here, we fit individual @entity0 data with a cumulative Gaussian to extract the mean and standard deviation of the distribution. The mean represents the point of subjective equality (PSE), the inter-stimulus interval at which @entity0 are equally likely to respond that two stimuli are one stimulus (synchronous) or two different stimuli (asynchronous). The standard deviation represents the just noticeable difference (JND) which is how sensitive @entity0 are to changes in temporal asynchrony around the PSE. We extended this method by submitting the data to a non-parametric bootstrapped analysis to get 95% confidence intervals on individual @entity0 data. MAIN RESULTS: Both the JND and PSE correlate with the TDT value but are independent of each other. Hence this suggests that they represent different facets of the TDT. Furthermore, we divided groups by age and compared the TDT, PSE, and JND values. The analysis revealed a statistical difference for the PSE which was only trending for the TDT. SIGNIFICANCE: The analysis method will enable deeper analysis of the TDT to leverage subtle differences within and between control and @entity0 groups, not apparent in the standard TDT measure.

title: Non-parametric bootstrapping method for measuring the temporal discrimination threshold for XXXX .

answer: @entity2


abstract: AIM: To estimate the impact of adherence with @entity3 inhibitor (PPI) therapy on the incidence of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy ( @entity1 ) in @entity0 with @entity2 ( @entity2 ). SUBJECTS AND METHODS: PPI pharmacotherapy adherence was estimated using the Medication Adherence Questionnaire (MAQ) in 92 @entity0 with @entity2 , including 32 @entity0 did not take a PPI and 60 used a PPI. The groups were matched for age, disease duration, and used NSAIDs. All those asked underwent video esophagogastroduodenoscopy. RESULTS: According to the data of MAQ survey, low, moderate, and high adherence subgroups could be identified among the @entity0 treated with a PPI. @entity1 was detected in 43.8% of the @entity0 taking no PPI, in 50% of those with low PPI treatment adherence, in 12.5% with moderate adherence, and in 4.5% with high adherence. In the @entity0 with low adherence to PPI therapy, @entity1 was recorded 11 times more frequently than in those with high adherence (c2 = 7.77; p = 0.005). This condition occurred in 28.6% of the @entity0 taking NSAID without preventively using a PPI in the absence of risk factors for @entity1 . CONCLUSION: Only 36.7% @entity0 who had been recommended to use a PPI for the prevention of @entity1 strictly observed their doctor's directions. Low PPI pharmacotherapy adherence may serve as an additional risk factor for @entity1 in @entity0 in whom preventive antisecretory therapy used in combination with NSAID is indicated.

title: [Adherence with XXXX inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs].

answer: @entity3


abstract: INTRODUCTION: Despite its high incidence, nerve fiber (axon and myelin) damage after @entity2 has not yet been extensively investigated. The aim of this study was to investigate white matter repair after adipose-derived mesenchymal stem cell (ADMSC) administration in an experimental model of subcortical @entity1 . Furthermore, we aimed to analyze the ADMSC secretome and whether this could be implicated in this repair function. METHODS: An animal model of subcortical @entity2 with white matter affectation was induced in @entity0 by injection of @entity3 . At 24 hours, 2 * 10(6) ADMSC were administered intravenously to the treatment group. Functional evaluation, lesion size, fiber tract integrity, cell death, proliferation, white matter repair markers ( @entity5 , NF, and @entity4 ) and NogoA were all studied after sacrifice (7 days and 28 days). ADMSC migration and implantation in the brain as well as proteomics analysis and functions of the secretome were also analyzed. RESULTS: Neither ADMSC migration nor implantation to the brain was observed after ADMSC administration. In contrast, ADMSC implantation was detected in peripheral organs. The treatment group showed a smaller functional deficit, smaller lesion area, less cell death, more oligodendrocyte proliferation, more white matter connectivity and higher amounts of myelin formation. The treated animals also showed higher levels of white matter-associated markers in the injured area than the control group. Proteomics analysis of the ADMSC secretome identified 2,416 proteins, not all of them previously described to be involved in brain plasticity. CONCLUSIONS: White matter integrity in subcortical @entity1 is in part restored by ADMSC treatment; this is mediated by repair molecular factors implicated in axonal sprouting, remyelination and oligodendrogenesis. These findings are associated with improved functional recovery after @entity1 .

title: White matter injury restoration after stem cell administration in subcortical XXXX .

answer: @entity2


abstract: UNASSIGNED: Degradation of @entity3 leads to the production of @entity3 -derived peptides (EDP), which exhibit several biological effects, such as cell proliferation or protease secretion. Binding of EDP on the @entity3 receptor complex (ERC) triggers @entity5 ( @entity6 ) production and @entity2 activation following ERC @entity1 subunit activation. The ability for ERC to transduce signals is lost during aging, but the mechanism involved is still unknown. In this study, we characterized an in vitro model of aging by subculturing @entity0 dermal fibroblasts. This model was used to understand the loss of EDP biological activities during aging. Our results show that ERC uncoupling does not rely on @entity1 or @entity4 mRNA or protein level changes. Furthermore, we observe that the membrane targeting of these subunits is not affected with aging. However, we evidence that @entity1 activity and @entity6 production are altered. Basal @entity1 catalytic activity is strongly increased in aged cells. Consequently, EDP fail to promote @entity1 catalytic activity and @entity6 production in these cells. In conclusion, we propose, for the first time, an explanation for ERC uncoupling based on the age-related alterations of @entity1 activity and @entity6 production that may explain the loss of EDP-mediated effects occurring during aging.

title: Uncoupling of @entity3 Complex Receptor during In Vitro Aging Is Related to Modifications in Its Intrinsic Sialidase Activity and the Subsequent XXXX Production.

answer: @entity5


abstract: UNASSIGNED: Degradation of @entity3 leads to the production of @entity3 -derived peptides (EDP), which exhibit several biological effects, such as cell proliferation or protease secretion. Binding of EDP on the @entity3 receptor complex (ERC) triggers @entity5 ( @entity6 ) production and @entity2 activation following ERC @entity1 subunit activation. The ability for ERC to transduce signals is lost during aging, but the mechanism involved is still unknown. In this study, we characterized an in vitro model of aging by subculturing @entity0 dermal fibroblasts. This model was used to understand the loss of EDP biological activities during aging. Our results show that ERC uncoupling does not rely on @entity1 or @entity4 mRNA or protein level changes. Furthermore, we observe that the membrane targeting of these subunits is not affected with aging. However, we evidence that @entity1 activity and @entity6 production are altered. Basal @entity1 catalytic activity is strongly increased in aged cells. Consequently, EDP fail to promote @entity1 catalytic activity and @entity6 production in these cells. In conclusion, we propose, for the first time, an explanation for ERC uncoupling based on the age-related alterations of @entity1 activity and @entity6 production that may explain the loss of EDP-mediated effects occurring during aging.

title: Uncoupling of XXXX Complex Receptor during In Vitro Aging Is Related to Modifications in Its Intrinsic Sialidase Activity and the Subsequent @entity5 Production.

answer: @entity3


abstract: IMPORTANCE: @entity1 are rare and represent a wide range of different benign and malignant pathologies. For an accurate and specific final diagnosis, biopsy procedures and/or resections followed by histologic examination are mandatory. OBJECTIVE: To illustrate the challenges in obtaining a final histologic diagnosis in @entity0 with various types of @entity1 . DESIGN, SETTING, AND @entity0 : We performed a retrospective analysis of medical records of 24 @entity0 who underwent endonasal endoscopic biopsy of the clivus between February 1, 2005, and June 1, 2013, in 2 medical university hospitals. Analysis was conducted between January 1 and August 15, 2014. INTERVENTIONS: All @entity0 underwent endoscopic biopsy of the clivus. MAIN OUTCOMES AND MEASURES: The number of biopsies performed to establish a diagnosis in @entity1 and the problems encountered when analyzing the radiologic findings and histologic results. RESULTS: In 14 of 24 @entity0 (58%), a conclusive histologic diagnosis of the @entity1 could be determined. Despite up to 3 endonasal endoscopic biopsies, the histologic result could not be clearly specified in the remaining 10 @entity0 (42%). No major complications occurred. Treatment based on the testing results included endonasal endoscopic surgery, radiotherapy or radiochemotherapy, and/or follow-up examination. CONCLUSIONS AND RELEVANCE: Challenges can occur in the radiologic evaluation and pathologic differentiation of diverse @entity2 with overlapping morphologic features as well as in the differentiation between neoplastic, reactive, inflammatory, and metabolic @entity2 and @entity3 . Despite more than 1 biopsy, histologic classification will not always lead to a definitive diagnosis. In such cases, an interdisciplinary team should decide whether additional biopsies should be performed or whether clinical, endoscopic, and radiologic controls are sufficient.

title: Challenges in Histologic Diagnosis of XXXX of the Clivus.

answer: @entity1


abstract: OBJECTIVE: Torsion of the omentum is a rare cause of acute surgical abdomen. Here we describe a case of a pregnant @entity0 with acute @entity2 and a perioperative diagnosis of @entity1 of torted omentum was made. DESIGN: Case report. SETTING: Department of Obstetrics and Gynaecology, Masaryks Hospital, Jilemnice. CASE REPORT: Thirty year old female @entity0 , who was 38 weeks pregnant, presented to our department with acute surgical abdomen. @entity3 was suspected and an urgent caesarean section followed by appendectomy was scheduled. However, perioperatively a necrotic part of torted omentum was identified and resected. CONCLUSION: Torsion of the omentum is a rare cause of acute @entity2 which is usually diagnosed only perioperatively. This condition usually presents with nonspecific symptoms and most commonly mimics @entity3 . Owing to, inexplicit symptoms and wide range of differential diagnoses it is important to think of this entity as a possible cause of acute @entity2 . Clear indication for abdominal surgery, especially in pregnant @entity0 is essential and requires efficient team working between gynaecologists, abdominal surgeons and radiologists.

title: [Torsion of the omentum - an unexpected cause of  acute surgical abdomen in a  pregnant XXXX -case report].

answer: @entity0


abstract: BACKGROUND: Although numerous recent advances in wound healing have highlighted the importance of adjunct therapies in maximizing healing potential, abnormal wound healing continues to cause significant expense, morbidity, and mortality. OBJECTIVE: This study examines the effects of @entity1 ( @entity2 ) on wound healing. HYPOTHESIS: We are expecting that @entity2 administration can increase biomechanical parameters and modulate @entity5 ( @entity5 ) and @entity4 , and matrix metalloproteinase inhibitor-1 ( @entity3 ) in normoglycemic (NG) @entity0 model of wound healing. METHODS: Each @entity0 received an identical wound from a full-thickness incision on its back. Experimental @entity0 received systemic administration of @entity2 . All @entity0 underwent examinations for biomechanical and polymerase chain reaction(PCR) analysis. Maximum stress and energy absorption were calculated as the biomechanical examinations. Expressions of @entity5 , @entity4 and @entity3 genes were evaluated semi-quantitatively by reverse transcriptional (RT)-PCR. RESULTS: @entity2 significantly improved biomechanical parameters. Quantification of @entity5 , @entity4 , and @entity3 showed that @entity2 significantly reduced gene expressions of @entity5 and @entity4 . There was a significant increase in @entity3 gene expression. CONCLUSION: Systemic administration of @entity2 significantly accelerated the wound healing process in NG @entity0 .

title: @entity1 Accelerates Wound Healing Process by Modulating Gene Expression of @entity5 , XXXX , and @entity3 in Normoglycemic @entity0 .

answer: @entity4


abstract: BACKGROUND: Although numerous recent advances in wound healing have highlighted the importance of adjunct therapies in maximizing healing potential, abnormal wound healing continues to cause significant expense, morbidity, and mortality. OBJECTIVE: This study examines the effects of @entity1 ( @entity2 ) on wound healing. HYPOTHESIS: We are expecting that @entity2 administration can increase biomechanical parameters and modulate @entity5 ( @entity5 ) and @entity4 , and matrix metalloproteinase inhibitor-1 ( @entity3 ) in normoglycemic (NG) @entity0 model of wound healing. METHODS: Each @entity0 received an identical wound from a full-thickness incision on its back. Experimental @entity0 received systemic administration of @entity2 . All @entity0 underwent examinations for biomechanical and polymerase chain reaction(PCR) analysis. Maximum stress and energy absorption were calculated as the biomechanical examinations. Expressions of @entity5 , @entity4 and @entity3 genes were evaluated semi-quantitatively by reverse transcriptional (RT)-PCR. RESULTS: @entity2 significantly improved biomechanical parameters. Quantification of @entity5 , @entity4 , and @entity3 showed that @entity2 significantly reduced gene expressions of @entity5 and @entity4 . There was a significant increase in @entity3 gene expression. CONCLUSION: Systemic administration of @entity2 significantly accelerated the wound healing process in NG @entity0 .

title: XXXX Accelerates Wound Healing Process by Modulating Gene Expression of @entity5 , @entity4 , and @entity3 in Normoglycemic @entity0 .

answer: @entity1


abstract: BACKGROUND: Although numerous recent advances in wound healing have highlighted the importance of adjunct therapies in maximizing healing potential, abnormal wound healing continues to cause significant expense, morbidity, and mortality. OBJECTIVE: This study examines the effects of @entity1 ( @entity2 ) on wound healing. HYPOTHESIS: We are expecting that @entity2 administration can increase biomechanical parameters and modulate @entity5 ( @entity5 ) and @entity4 , and matrix metalloproteinase inhibitor-1 ( @entity3 ) in normoglycemic (NG) @entity0 model of wound healing. METHODS: Each @entity0 received an identical wound from a full-thickness incision on its back. Experimental @entity0 received systemic administration of @entity2 . All @entity0 underwent examinations for biomechanical and polymerase chain reaction(PCR) analysis. Maximum stress and energy absorption were calculated as the biomechanical examinations. Expressions of @entity5 , @entity4 and @entity3 genes were evaluated semi-quantitatively by reverse transcriptional (RT)-PCR. RESULTS: @entity2 significantly improved biomechanical parameters. Quantification of @entity5 , @entity4 , and @entity3 showed that @entity2 significantly reduced gene expressions of @entity5 and @entity4 . There was a significant increase in @entity3 gene expression. CONCLUSION: Systemic administration of @entity2 significantly accelerated the wound healing process in NG @entity0 .

title: @entity1 Accelerates Wound Healing Process by Modulating Gene Expression of @entity5 , @entity4 , and @entity3 in Normoglycemic XXXX .

answer: @entity0


abstract: BACKGROUND: Although numerous recent advances in wound healing have highlighted the importance of adjunct therapies in maximizing healing potential, abnormal wound healing continues to cause significant expense, morbidity, and mortality. OBJECTIVE: This study examines the effects of @entity1 ( @entity2 ) on wound healing. HYPOTHESIS: We are expecting that @entity2 administration can increase biomechanical parameters and modulate @entity5 ( @entity5 ) and @entity4 , and matrix metalloproteinase inhibitor-1 ( @entity3 ) in normoglycemic (NG) @entity0 model of wound healing. METHODS: Each @entity0 received an identical wound from a full-thickness incision on its back. Experimental @entity0 received systemic administration of @entity2 . All @entity0 underwent examinations for biomechanical and polymerase chain reaction(PCR) analysis. Maximum stress and energy absorption were calculated as the biomechanical examinations. Expressions of @entity5 , @entity4 and @entity3 genes were evaluated semi-quantitatively by reverse transcriptional (RT)-PCR. RESULTS: @entity2 significantly improved biomechanical parameters. Quantification of @entity5 , @entity4 , and @entity3 showed that @entity2 significantly reduced gene expressions of @entity5 and @entity4 . There was a significant increase in @entity3 gene expression. CONCLUSION: Systemic administration of @entity2 significantly accelerated the wound healing process in NG @entity0 .

title: @entity1 Accelerates Wound Healing Process by Modulating Gene Expression of @entity5 , @entity4 , and XXXX in Normoglycemic @entity0 .

answer: @entity3


abstract: BACKGROUND: Although numerous recent advances in wound healing have highlighted the importance of adjunct therapies in maximizing healing potential, abnormal wound healing continues to cause significant expense, morbidity, and mortality. OBJECTIVE: This study examines the effects of @entity1 ( @entity2 ) on wound healing. HYPOTHESIS: We are expecting that @entity2 administration can increase biomechanical parameters and modulate @entity5 ( @entity5 ) and @entity4 , and matrix metalloproteinase inhibitor-1 ( @entity3 ) in normoglycemic (NG) @entity0 model of wound healing. METHODS: Each @entity0 received an identical wound from a full-thickness incision on its back. Experimental @entity0 received systemic administration of @entity2 . All @entity0 underwent examinations for biomechanical and polymerase chain reaction(PCR) analysis. Maximum stress and energy absorption were calculated as the biomechanical examinations. Expressions of @entity5 , @entity4 and @entity3 genes were evaluated semi-quantitatively by reverse transcriptional (RT)-PCR. RESULTS: @entity2 significantly improved biomechanical parameters. Quantification of @entity5 , @entity4 , and @entity3 showed that @entity2 significantly reduced gene expressions of @entity5 and @entity4 . There was a significant increase in @entity3 gene expression. CONCLUSION: Systemic administration of @entity2 significantly accelerated the wound healing process in NG @entity0 .

title: @entity1 Accelerates Wound Healing Process by Modulating Gene Expression of XXXX , @entity4 , and @entity3 in Normoglycemic @entity0 .

answer: @entity5


abstract: UNASSIGNED: Disturbance associated with severe wildfires (WF) and WF simulating harvest operations can potentially alter soil @entity0 ( @entity1 ) oxidation in well-aerated forest soils due to the effect on soil properties linked to diffusivity, methanotrophic activity or changes in methanotrophic bacterial community structure. However, changes in soil @entity1 flux related to such disturbances are still rarely studied even though WF frequency is predicted to increase as a consequence of global climate change. We measured in-situ soil-atmosphere @entity1 exchange along a wet sclerophyll eucalypt forest regeneration chronosequence in Tasmania, Australia, where the time since the last severe fire or harvesting disturbance ranged from 9 to >200  years. On all sampling occasions, mean @entity1 uptake increased from most recently disturbed sites (9  year) to sites at stand 'maturity' (44 and 76  years). In stands >76  years since disturbance, we observed a decrease in soil @entity1 uptake. A similar age dependency of potential @entity1 oxidation for three soil layers (0.0-0.05, 0.05-0.10, 0.10-0.15  m) could be observed on incubated soils under controlled laboratory conditions. The differences in soil @entity1 uptake between forest stands of different age were predominantly driven by differences in soil moisture status, which affected the diffusion of atmospheric @entity1 into the soil. The observed soil moisture pattern was likely driven by changes in interception or evapotranspiration with forest age, which have been well described for similar eucalypt forest systems in south-eastern Australia. Our results imply that there is a large amount of variability in @entity1 uptake at a landscape scale that can be attributed to stand age and soil moisture differences. An increase in severe WF frequency in response to climate change could potentially increase overall forest soil @entity1 sinks.

title: Changes in soil moisture drive soil XXXX uptake along a fire regeneration chronosequence in a eucalypt forest landscape.

answer: @entity0


abstract: UNASSIGNED: @entity1 is a common diagnosis and leading cause of @entity2 worldwide. Amounts of @entity4 vary but it is associated with considerable morbidity, poorer quality of life and reduced survival. Nutritional intervention has the potential to maximise response to treatment and improve functioning and quality of life. The aim of this paper was to review the evidence for oral nutritional interventions in the management of @entity4 in @entity0 with @entity1 . Comparison of studies of nutritional support interventions in @entity0 with @entity1 is complicated by variations in understanding of what constitutes a compromised nutritional status. There are similarities and differences between definitions of both @entity6 and @entity5 and studies of oral nutritional interventions have failed to use standard criteria at study inclusion contributing to heterogeneity amongst studies. Meta-analysis of randomised controlled trials has suggested limited evidence of benefit to nutritional and clinical outcomes but some improvements to aspects of quality of life. The presence of @entity5 in @entity0 with @entity1 might explain the limited efficacy of simple oral nutritional interventions, which lack a component designed to address @entity3 associated with @entity5 . Novel strategies combining nutritional support with therapeutic agents designed to down-regulate the metabolic aberrations have failed to demonstrate consistent benefits and the results of multimodal treatments combining several interventions are awaited. There is a need for intervention studies recruiting @entity0 early in the disease course, which underlines the need for definitions which predict poor outcome and hence allow early recognition of vulnerable @entity0 .

title: The effectiveness of nutritional interventions in @entity6 and XXXX .

answer: @entity5


abstract: UNASSIGNED: @entity1 is a common diagnosis and leading cause of @entity2 worldwide. Amounts of @entity4 vary but it is associated with considerable morbidity, poorer quality of life and reduced survival. Nutritional intervention has the potential to maximise response to treatment and improve functioning and quality of life. The aim of this paper was to review the evidence for oral nutritional interventions in the management of @entity4 in @entity0 with @entity1 . Comparison of studies of nutritional support interventions in @entity0 with @entity1 is complicated by variations in understanding of what constitutes a compromised nutritional status. There are similarities and differences between definitions of both @entity6 and @entity5 and studies of oral nutritional interventions have failed to use standard criteria at study inclusion contributing to heterogeneity amongst studies. Meta-analysis of randomised controlled trials has suggested limited evidence of benefit to nutritional and clinical outcomes but some improvements to aspects of quality of life. The presence of @entity5 in @entity0 with @entity1 might explain the limited efficacy of simple oral nutritional interventions, which lack a component designed to address @entity3 associated with @entity5 . Novel strategies combining nutritional support with therapeutic agents designed to down-regulate the metabolic aberrations have failed to demonstrate consistent benefits and the results of multimodal treatments combining several interventions are awaited. There is a need for intervention studies recruiting @entity0 early in the disease course, which underlines the need for definitions which predict poor outcome and hence allow early recognition of vulnerable @entity0 .

title: The effectiveness of nutritional interventions in XXXX and @entity5 .

answer: @entity6


abstract: UNASSIGNED: @entity5 ( @entity5 ) present with abnormalities of circadian rhythmicity and sleep homeostasis, even during phases of remission. These abnormalities are linked to the underlying neurobiology of and genetic susceptibility to @entity5 . @entity8 is a pineal gland secreted neurohormone that induces circadian-related and sleep-related responses. Exogenous @entity8 has demonstrated efficacy in treating @entity1 , delayed sleep @entity3 , improving sleep parameters and overall sleep quality, and some @entity4 disorders like @entity7 . In order to evaluate the efficacy of @entity8 among @entity0 with @entity5 , this comprehensive review emphasizes the abnormal @entity8 function in @entity5 , the rationale of @entity8 action in @entity5 , the available data about the exogenous administration of @entity8 , and @entity8 agonists (ramelteon and @entity9 ), and recommendations of use in @entity0 with @entity5 . There is a scientific rationale to propose @entity8 -agonists as an adjunctive treatment of mood stabilizers in treating @entity2 in @entity5 and thus to possibly prevent relapses when administered during remission phases. We emphasized the need to treat @entity1 , sleep delayed latencies and @entity2 in @entity5 are prodromal markers of an emerging mood episode and possible targets to prevent future relapses. An additional interesting adjunctive therapeutic effect might be on preventing @entity6 , particularly in @entity0 treated with antipsychotics. Finally, @entity8 is well tolerated and has little dependence potential in contrast to most available sleep medications. Future studies are expected to be able to produce stronger evidence-based therapeutic guidelines to confirm and delineate the routine use of @entity8 -agonists in the treatment of @entity5 .

title: XXXX AND @entity8 AGONISTS AS ADJUNCTIVE TREATMENTS IN BIPOLAR DISORDERS.

answer: @entity8


abstract: UNASSIGNED: @entity5 ( @entity5 ) present with abnormalities of circadian rhythmicity and sleep homeostasis, even during phases of remission. These abnormalities are linked to the underlying neurobiology of and genetic susceptibility to @entity5 . @entity8 is a pineal gland secreted neurohormone that induces circadian-related and sleep-related responses. Exogenous @entity8 has demonstrated efficacy in treating @entity1 , delayed sleep @entity3 , improving sleep parameters and overall sleep quality, and some @entity4 disorders like @entity7 . In order to evaluate the efficacy of @entity8 among @entity0 with @entity5 , this comprehensive review emphasizes the abnormal @entity8 function in @entity5 , the rationale of @entity8 action in @entity5 , the available data about the exogenous administration of @entity8 , and @entity8 agonists (ramelteon and @entity9 ), and recommendations of use in @entity0 with @entity5 . There is a scientific rationale to propose @entity8 -agonists as an adjunctive treatment of mood stabilizers in treating @entity2 in @entity5 and thus to possibly prevent relapses when administered during remission phases. We emphasized the need to treat @entity1 , sleep delayed latencies and @entity2 in @entity5 are prodromal markers of an emerging mood episode and possible targets to prevent future relapses. An additional interesting adjunctive therapeutic effect might be on preventing @entity6 , particularly in @entity0 treated with antipsychotics. Finally, @entity8 is well tolerated and has little dependence potential in contrast to most available sleep medications. Future studies are expected to be able to produce stronger evidence-based therapeutic guidelines to confirm and delineate the routine use of @entity8 -agonists in the treatment of @entity5 .

title: @entity8 AND XXXX AGONISTS AS ADJUNCTIVE TREATMENTS IN BIPOLAR DISORDERS.

answer: @entity8


abstract: Purpose. To present the clinical and histopathologic correlation of two cases of @entity2 ( @entity2 ) after prior intraocular surgery. Methods. Observational case reports. Results. We present two cases of @entity2 occurring after intraocular surgery. In both cases, after two anterior chamber injections of @entity1 ( @entity1 ), the area of @entity2 initially regressed. In Case 1, a limited area of @entity2 eventually recurred, and penetrating keratoplasty with cryotherapy was curative. In Case 2, subsequent @entity3 required Descemet-stripping automated endothelial keratoplasty, and the @entity0 remained clinically free of @entity2 without further treatment. Conclusion. Intracameral @entity1 may have a role in the treatment of @entity2 after intraocular surgery, though its precise utilization and impact remain to be defined.

title: Epithelial Downgrowth after Intraocular Surgery Treated with Intracameral XXXX .

answer: @entity1


abstract: UNASSIGNED: The aim of this study was to compare the protective effects of solutions containing stannous (Sn), @entity2 (F) and their combination in the prevention of dentin @entity4 . Forty @entity1 root dentin specimens (4'4'2 mm3) were prepared and randomly assigned to 4 groups (n = 10): @entity7 (800 ppm/6.7 mM Sn), @entity6 (250 ppm/13 mM F), @entity6 / @entity7 (800 ppm/6.7 mM Sn; 250 ppm/13 mM F), and deionized water (DIW) as a negative control. An acquired pellicle was formed on dentin samples by incubation in clarified, pooled, stimulated @entity0 saliva for 24 hours. The specimens were subjected to 5 daily cycles, each consisting of 5 of min @entity5 (0.3%/15.6 mM @entity3 , pH 2.6, 6'/day) and 60 min of re-mineralization in clarified @entity0 saliva. Thirty minutes after the 1st, 3rd and 5th @entity5 episodes of each day, the specimens were treated with one of the test solutions for 2 min. Surface loss was measured via optical profilometry. Mixed-model ANOVA followed by Tukey's test were used for the statistical analysis. Sn, F, and their combination significantly reduced the dentin surface loss by 23%, 36%, and 60% compared with DIW, respectively. All groups were significantly different (p < 0.05). The combination of Sn and F significantly reduced the amount of dentin surface loss compared with all other groups. The F group also significantly reduced surface loss compared with Sn and DIW, followed by the Sn group, which showed significantly greater protection compared with the DIW control. The daily use of a combined @entity2 and stannous solution is promising for preventing dentin @entity4 .

title: Efficacy of stannous, XXXX and their their combination in dentin @entity4 prevention in vitro.

answer: @entity2


abstract: UNASSIGNED: The aim of this study was to compare the protective effects of solutions containing stannous (Sn), @entity2 (F) and their combination in the prevention of dentin @entity4 . Forty @entity1 root dentin specimens (4'4'2 mm3) were prepared and randomly assigned to 4 groups (n = 10): @entity7 (800 ppm/6.7 mM Sn), @entity6 (250 ppm/13 mM F), @entity6 / @entity7 (800 ppm/6.7 mM Sn; 250 ppm/13 mM F), and deionized water (DIW) as a negative control. An acquired pellicle was formed on dentin samples by incubation in clarified, pooled, stimulated @entity0 saliva for 24 hours. The specimens were subjected to 5 daily cycles, each consisting of 5 of min @entity5 (0.3%/15.6 mM @entity3 , pH 2.6, 6'/day) and 60 min of re-mineralization in clarified @entity0 saliva. Thirty minutes after the 1st, 3rd and 5th @entity5 episodes of each day, the specimens were treated with one of the test solutions for 2 min. Surface loss was measured via optical profilometry. Mixed-model ANOVA followed by Tukey's test were used for the statistical analysis. Sn, F, and their combination significantly reduced the dentin surface loss by 23%, 36%, and 60% compared with DIW, respectively. All groups were significantly different (p < 0.05). The combination of Sn and F significantly reduced the amount of dentin surface loss compared with all other groups. The F group also significantly reduced surface loss compared with Sn and DIW, followed by the Sn group, which showed significantly greater protection compared with the DIW control. The daily use of a combined @entity2 and stannous solution is promising for preventing dentin @entity4 .

title: Efficacy of stannous, @entity2 and their their combination in dentin XXXX prevention in vitro.

answer: @entity4


abstract: OBJECTIVES: Fixed-dose combination formulations, which simplify the administration of drugs and prevent the development of drug resistance, have been recommended as a standard anti- @entity1 treatment regimen. However, the composition and dosage recommendations for fixed-dose combination formulations differ from those for separate formulations. Thus, questions about the effectiveness and side effects of combination formulations remain. The aim of this study was to compare the safety and efficacy of these two types of anti- @entity1 regimens for @entity3 treatment. METHOD: A prospective, randomized controlled study was conducted using the directly observed treatment short-course strategy. @entity0 were randomly allocated to one of two short-course regimens. One year after completing the treatment, these @entity0 ' outcomes were analyzed. ClinicalTrials.gov: NCT00979290. RESULTS: A total of 161 @entity0 were enrolled, 142 of whom were evaluable for safety assessment. The two regimens had a similar incidence of adverse effects. In the per-protocol population, serum @entity2 concentrations at the peak level, at week 4, and at week 8 were significantly higher for the fixed-dose combination formulation than for the separate formulations. All @entity0 had negative sputum cultures at the end of the treatment, and no relapse occurred after one year of follow-up. CONCLUSIONS: In this randomized study, transient higher serum @entity2 levels were noted for the fixed-dose combination regimen compared with the separate formulations during treatment. However, no significant difference in safety or efficacy was found between the groups when the directly observed treatment short-course strategy was used.

title: Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for XXXX treatment.

answer: @entity3


abstract: BACKGROUND: The injury pattern from @entity5 ( @entity5 ) @entity1 is different if the target is in a vehicle (mounted) or on foot (dismounted). Combat and civilian first response protocols require the placement of a cervical collar on all victims of a @entity6 . METHODS: We searched the Joint Theatre Trauma Registry (JTTR) and the Role 3 Hospital, Kandahar Airfield (KAF) database from Mar. 1, 2008, to May 31, 2011. We collected data on cervical @entity2 ; @entity3 ; @entity1 amputation; initial blood pressure, pulse, injury severity score (ISS), Glasgow @entity4 Scale (GCS) score and base excess; and @entity0 demographic information. RESULTS: The concordance rate between JTTR and KAF databases was 98%. Of the 15 693 admissions in JTTR, 326 @entity0 with dismounted @entity5 injuries were located. The rate of cervical collar prehospital placement was 7.6%. @entity2 were found in 19 (5.8%) dismounted @entity5 victims, but only 4 (1.2%) were considered radiographically unstable. None of these 19 @entity0 had prehospital placement of a collar. @entity0 with cervical spine fractures were more severely injured than those without (ISS 18.2 v. 13.4; GCS 10.1 v. 12.5). @entity0 with @entity3 had significantly higher risk of cervical @entity1 than those with no @entity3 recorded (13.6% v. 3.9%). No differences in frequency of cervical @entity1 were found between @entity0 who had associated @entity1 amputations and those who did not (5.4% v. 6.0%). CONCLUSION: Dismounted @entity5 is a mechanism of injury associated with a low risk for cervical spine @entity1 . A selective protocol for cervical collar placement on victims of dismounted @entity5 blasts is possible and may be more amenable to combat situations.

title: XXXX in dismounted @entity5 @entity1 .

answer: @entity1


abstract: BACKGROUND: The injury pattern from @entity5 ( @entity5 ) @entity1 is different if the target is in a vehicle (mounted) or on foot (dismounted). Combat and civilian first response protocols require the placement of a cervical collar on all victims of a @entity6 . METHODS: We searched the Joint Theatre Trauma Registry (JTTR) and the Role 3 Hospital, Kandahar Airfield (KAF) database from Mar. 1, 2008, to May 31, 2011. We collected data on cervical @entity2 ; @entity3 ; @entity1 amputation; initial blood pressure, pulse, injury severity score (ISS), Glasgow @entity4 Scale (GCS) score and base excess; and @entity0 demographic information. RESULTS: The concordance rate between JTTR and KAF databases was 98%. Of the 15 693 admissions in JTTR, 326 @entity0 with dismounted @entity5 injuries were located. The rate of cervical collar prehospital placement was 7.6%. @entity2 were found in 19 (5.8%) dismounted @entity5 victims, but only 4 (1.2%) were considered radiographically unstable. None of these 19 @entity0 had prehospital placement of a collar. @entity0 with cervical spine fractures were more severely injured than those without (ISS 18.2 v. 13.4; GCS 10.1 v. 12.5). @entity0 with @entity3 had significantly higher risk of cervical @entity1 than those with no @entity3 recorded (13.6% v. 3.9%). No differences in frequency of cervical @entity1 were found between @entity0 who had associated @entity1 amputations and those who did not (5.4% v. 6.0%). CONCLUSION: Dismounted @entity5 is a mechanism of injury associated with a low risk for cervical spine @entity1 . A selective protocol for cervical collar placement on victims of dismounted @entity5 blasts is possible and may be more amenable to combat situations.

title: @entity1 in dismounted @entity5 XXXX .

answer: @entity1


abstract: BACKGROUND: The injury pattern from @entity5 ( @entity5 ) @entity1 is different if the target is in a vehicle (mounted) or on foot (dismounted). Combat and civilian first response protocols require the placement of a cervical collar on all victims of a @entity6 . METHODS: We searched the Joint Theatre Trauma Registry (JTTR) and the Role 3 Hospital, Kandahar Airfield (KAF) database from Mar. 1, 2008, to May 31, 2011. We collected data on cervical @entity2 ; @entity3 ; @entity1 amputation; initial blood pressure, pulse, injury severity score (ISS), Glasgow @entity4 Scale (GCS) score and base excess; and @entity0 demographic information. RESULTS: The concordance rate between JTTR and KAF databases was 98%. Of the 15 693 admissions in JTTR, 326 @entity0 with dismounted @entity5 injuries were located. The rate of cervical collar prehospital placement was 7.6%. @entity2 were found in 19 (5.8%) dismounted @entity5 victims, but only 4 (1.2%) were considered radiographically unstable. None of these 19 @entity0 had prehospital placement of a collar. @entity0 with cervical spine fractures were more severely injured than those without (ISS 18.2 v. 13.4; GCS 10.1 v. 12.5). @entity0 with @entity3 had significantly higher risk of cervical @entity1 than those with no @entity3 recorded (13.6% v. 3.9%). No differences in frequency of cervical @entity1 were found between @entity0 who had associated @entity1 amputations and those who did not (5.4% v. 6.0%). CONCLUSION: Dismounted @entity5 is a mechanism of injury associated with a low risk for cervical spine @entity1 . A selective protocol for cervical collar placement on victims of dismounted @entity5 blasts is possible and may be more amenable to combat situations.

title: @entity1 in dismounted XXXX @entity1 .

answer: @entity5


abstract: PURPOSE: This study aimed to evaluate the efficacy of @entity3 (PI) 5% as the only preoperative antiseptic in @entity2 surgery. DESIGN: Prospective interventional case series. METHODS: Fifty @entity0 undergoing phacoemulsification under topical anesthesia in an outpatient surgery setting in a teaching hospital participated in the study. The preoperative antiseptic regimen consisted of instillation into the conjunctival sac and periorbital scrub with PI 5%. No topical antibiotic was given. Eyelid margin swabs were obtained for bacteriological culture before and after PI antisepsis and at the conclusion of surgery. The number of bacterial species isolated was compared with the Wilcoxon test. Anterior chamber aspirates were taken immediately before and after surgery to determine the rate of contamination. RESULTS: Bacteria were isolated from the eyelid margins of 48 @entity0 (96%; 95% exact confidence interval, 86.3%-99.5%) before surgery, from the eyelid margins of 28 @entity0 (56%) after antisepsis with PI 5%, and from the eyelid margins of 26 @entity0 (56%; 95% exact confidence interval, 41.3%-70.0%) at the conclusion of surgery. The reduction of positive eyelid margin culture was statistically significant (P < 0.0001). Anterior chamber aspirates were positive in 3 @entity0 . One @entity0 with negative growth from anterior chamber aspirates developed culture-negative @entity1 . CONCLUSIONS: Because 56% of eyelids still have positive culture after PI 5% antisepsis, it might not be relied on as the sole preoperative antiseptic measure. Meticulous surgical technique, together with other modalities of preoperative and intraoperative antisepsis, should be used to prevent @entity1 .

title: Preoperative Antisepsis With Povidone-Iodine 5% in XXXX Surgery.

answer: @entity2


abstract: UNASSIGNED: Vascular endothelial growth factors (VEGFs) play important roles in angiogenesis. In this study, a @entity0 named TjsvVEGF was purified from the venom of Trimeresurus jerdonii by gel filtration, affinity, ion-exchange and high-performance liquid chromatography. TjsvVEGF was a homodimer with an apparent molecular mass of 29  kDa. The cDNA encoding TjsvVEGF was obtained by PCR. The open reading frame of the cloned TjsvVEGF was composed of 432 bp coding for a signal peptide of 24 @entity1 residues and a mature protein of 119 @entity1 residues. Compared with other snake venom VEGFs, the @entity2 and deduced protein sequences of the cloned TjsvVEGF were conserved. TjsvVEGF showed low heparin binding activity and strong capillary permeability increasing activity. The KD of TjsvVEGF to VEFGR-2 is 413 pM. However, the binding of TjsvVEGF to @entity3 is too weak to detect. Though TjsvVEGF had high sequence identities (about 90%) with Crotalinae VEGFs, the receptor preference of TjsvVEGF was similar to Viperinae VEGFs which had lower sequence identities (about 60%) with it. TjsvVEGF might serve as a useful tool for the study of structure-function relationships of VEGFs and their receptors.

title: XXXX from Trimeresurus jerdonii venom specifically binds to VEGFR-2.

answer: @entity0


abstract: OBJECTIVE: a) to propose and implement an evaluation system; b) to classify the @entity1 and determine levels of physical therapy; c) to check the progress postoperatively. METHODS: @entity0 underwent physiotherapy assessment preoperatively, postoperatively and after 5 days of intervention. They were classified into three levels of care: level 1 - low risk of complication; Level 2 - medium risk; Level 3 - high risk. We used analysis of variance and Kruskal-Wallis and analysis of variance for repeated measures or Friedman. Chi-square test or Fisher for proportions. We considered statistical significance level P<0.05. RESULTS: We studied 199 @entity0 , 156 classified within level 1, 32 at level 2 and 11 at level 3. Thoracoabdominal motion and auscultation changed significantly postoperatively, persisting at levels 2 and 3 (P<0.05). Oxygenation and respiratory rate changed at levels 2 and 3 postoperatively (P<0.05) with recovery at the end. Significant decrease in lung volumes occurred in three levels (P<0.05) with partial recovery at level 1, @entity2 occurred at all levels, with recovery by 56% at level 1, 47% at level 2, 27% at level 3. CONCLUSION: The proposed assessment identified valve surgery @entity0 who require differentiated physical therapy. Level 1 @entity0 had rapid recovery, while the level 2 showed significant changes with functional gains at the end. Level 3 @entity0 , more committed and prolonged recovery, should receive greater assistance.

title: A propose of XXXX stratification after valve surgery by physiotherapeutic assistance level.

answer: @entity1


abstract: @entity14 ( @entity14 ) ( @entity16 ) is a @entity15 associated with @entity13 of the face, @entity3 , @entity8 , and usually ipsilateral @entity6 . The classic form affects leptomeninges, eyes, and face. Although the precise etiology and pathogenesis are unclear, the @entity1 is primary @entity9 with failure of the primordial embryonic venous plexus to regress. A spontaneous somatic mutation in fibroblast fibronectin gene expression in the @entity10 may occur during embryonic development. Ocular involvement is characterized by conjunctival, episcleral, @entity17 , and @entity4 . The @entity4 have been inconsistently described as @entity12 , @entity12 , and @entity10 . Based on the endothelial cellular activity, they can be @entity10 (or @entity13 ), which never regress spontaneously. Congenital, developmental, and adult-onset @entity7 are often seen when the @entity5 involve the distribution of the first branch of the trigeminal nerve.Both mechanical and vascular causes have been proposed to account for the development of @entity7 . The mechanical theory is based on obstruction of aqueous outflow secondary to developmental anterior chamber angle abnormalities, and the vascular theory is based primarily on elevated episcleral venous pressure. Management of @entity7 in @entity0 with @entity14 is often challenging and is aimed at controlling intraocular pressure and preventing progressive @entity2 and @entity11 . It also carries an increased risk for surgical complications. This review summarizes the literature regarding the genetics, clinical features, and management of ocular complications of @entity14 with special focus on @entity7 .

title: @entity16 ( XXXX , Klippel-Trenaunay-Weber Syndrome): A Review.

answer: @entity14


abstract: @entity14 ( @entity14 ) ( @entity16 ) is a @entity15 associated with @entity13 of the face, @entity3 , @entity8 , and usually ipsilateral @entity6 . The classic form affects leptomeninges, eyes, and face. Although the precise etiology and pathogenesis are unclear, the @entity1 is primary @entity9 with failure of the primordial embryonic venous plexus to regress. A spontaneous somatic mutation in fibroblast fibronectin gene expression in the @entity10 may occur during embryonic development. Ocular involvement is characterized by conjunctival, episcleral, @entity17 , and @entity4 . The @entity4 have been inconsistently described as @entity12 , @entity12 , and @entity10 . Based on the endothelial cellular activity, they can be @entity10 (or @entity13 ), which never regress spontaneously. Congenital, developmental, and adult-onset @entity7 are often seen when the @entity5 involve the distribution of the first branch of the trigeminal nerve.Both mechanical and vascular causes have been proposed to account for the development of @entity7 . The mechanical theory is based on obstruction of aqueous outflow secondary to developmental anterior chamber angle abnormalities, and the vascular theory is based primarily on elevated episcleral venous pressure. Management of @entity7 in @entity0 with @entity14 is often challenging and is aimed at controlling intraocular pressure and preventing progressive @entity2 and @entity11 . It also carries an increased risk for surgical complications. This review summarizes the literature regarding the genetics, clinical features, and management of ocular complications of @entity14 with special focus on @entity7 .

title: XXXX ( @entity14 , Klippel-Trenaunay-Weber Syndrome): A Review.

answer: @entity16


abstract: UNASSIGNED: Objective means are needed to predict and assess clinical response in @entity0 treated for @entity1 ( @entity1 ). We examined whether early changes in serum galactomannan (GM) and/or b-D-glucan (BDG) can predict clinical outcomes. @entity0 with proven or probable @entity1 were prospectively enrolled, and serial GM and BDG levels and GM optical density indices (GMI) were calculated twice weekly for 6 weeks following initiation of standard-of-care antifungal therapy. Changes in these biomarkers during the first 2 and 6 weeks of treatment were analyzed for associations with clinical response and survival at weeks 6 and 12. Among 47 @entity0 with @entity1 , 53.2% (25/47) and 65.9% (27/41) had clinical response by weeks 6 and 12, respectively. Changes in biomarkers during the first 2 weeks were associated with clinical response at 6 weeks (GMI, P = 0.03) and 12 weeks (GM+BDG composite, P = 0.05; GM, P = 0.04; GMI, P = 0.02). Changes in biomarkers during the first 6 weeks were also associated with clinical response at 6 weeks (GM, P = 0.05; GMI, P = 0.03) and 12 weeks (BDG+GM, P = 0.02; GM, P = 0.02; GMI, P = 0.01). Overall survival rates at 6 weeks and 12 weeks were 87.2% (41/47) and 79.1% (34/43), respectively. Decreasing biomarkers in the first 2 weeks were associated with survival at 6 weeks (BDG+GM, P = 0.03; BDG, P = 0.01; GM, P = 0.03) and at 12 weeks (BDG+GM, P = 0.01; BDG, P = 0.03; GM, P = 0.01; GMI, P = 0.007). Similar correlations occurred for biomarkers measured over 6 weeks. @entity0 with negative baseline GMI and/or persistently negative GMI during the first 2 weeks were more likely to have CR and survival. These results suggest that changes of biomarkers may be informative to predict and/or assess response to therapy and survival in @entity0 treated for @entity1 .

title: Correlation between Circulating Fungal Biomarkers and Clinical Outcome in XXXX .

answer: @entity1


abstract: PURPOSE: To determine the frequency of @entity1 ) in the placenta, in the colostrum and in the umbilical cord blood of parturient @entity0 and their newborns assisted at the Clinic of Gynecology and Obstetrics of the University Hospital of Rio Grande (RS), Brazil. METHODS: Biopsies were collected from 150 placentas on the maternal side, 150 on the fetal side, 138 samples of umbilical cord blood and 118 of the colostrum. The placenta biopsies were collected from the central and peripheral portions. DNA was extracted according to the manufacturer's protocol and to a reference found in the literature. HPV was detected by the nested polymerase chain reaction (PCR-Nested) using primers MY09/11 and @entity4 / @entity3 . Genotyping was performed by direct sequencing. The @entity0 responded to a self-applied questionnaire with demographic and clinical data, in order to characterize the sample. RESULTS: HPV was detected in 4% (6/150) of cases on the mother's side of the placentas, in 3.3% (5/150) on the fetal side, in 2.2% (3/138) in umbilical cord blood and in 0.84% (1/118) in colostrum samples. The vertical transmission rate was 50%. HPV-6 was the low-risk genotype found (60%) and the high-risk genotypes were @entity2 and HPV-18 (20% each). CONCLUSIONS: These results suggest that HPV can infect the placenta, the colostrum and the umbilical cord blood.

title: [Frequency of XXXX in the placenta, in the colostrum and in the umbilical cord blood].

answer: @entity1


abstract: PURPOSE: The purpose of this study was to characterize central @entity4 (CRVO) with inflammatory etiology. DESIGN: A retrospective study. METHODS: We retrospectively reviewed 51 eyes of 48 @entity0 with CRVO between 2004 and 2009 and investigated whether they had inflammatory findings related to @entity5 , that is, severe peripheral retinal vascular changes based on @entity3 angiography and anterior vitreous cells. The extent of vascular leakage was classified as "mild," "moderate," and "severe" in angiographic images. RESULTS: Six eyes of 5 @entity0 (11.8%) had both inflammatory criteria. All @entity0 were male and with a diagnosis of @entity1 CRVO. No causative etiology was detected in any @entity0 . The mean age was 46.4 (SD, 23.3) years. The age range was not limited to young generation. These @entity0 received systemic @entity2 therapy with a mean follow-up period of 41.8 months. The mean logMAR visual acuity [1.29 (SD, 0.77)] and central retinal thickness [1290.5 (SD, 399.0)  m)] at the initial visit were significantly (P = 0.004 and P = 0.001) improved at the final visit [0.94 (SD, 0.69) and 266.7 (SD, 135.4)  m, respectively]. CONCLUSIONS: Central @entity4 with idiopathic inflammatory conditions appears to have clinical characteristics of broad age range and good response to systemic corticosteroid therapy.

title: Clinical Features of Central XXXX With Inflammatory Etiology.

answer: @entity4


abstract: OBJECTIVE: To assess the trabecular bone structure of jawbones and the dens (the odontoid process of the second cervical vertebra) amongst @entity2 and nonosteoporotic @entity0 using cone-beam computed tomography (CBCT). Analysis of the dens trabecular bone structure aimed to test the validity of CBCT in such analysis. METHODS: Thirty-eight @entity0 who went under dual-energy X-ray absorptiometry (DXA) examination were scanned by CBCT. Cuboids from different areas of jawbones and the dens were extracted from each scan. Trabecular thickness (Tb.Th), trabecular separation (Tb.S), bone volume fraction (BV/TV), specific bone surface (BS/TV) and connectivity density were calculated. Student's t-test, Pearson correlation, and logistic regression analysis were used to explore differences in these measures between groups. RESULTS: Jawbone-derived measures showed insignificant differences (P  >  0.05) between @entity2 , and weak correlations with femoral neck and lumbar vertebrae T-scores (r   <=  0.4). Dens-derived measures, however, resulted in the opposite (r  =  0.34-0.38 [P  value  =  0.02-0.036] and r  =  0.48-0.61 [P  value   <=  0.003]) and the highest accuracy of @entity1 prediction: 84.2% and 78.9% respectively. CONCLUSION: Trabecular bone structure of the mandible and maxilla is not affected in @entity1 as assessed by CBCT. Dens trabecular bone analysis revealed the opposite, so some trabecular bone measures may be assessed by CBCT, which may aid in predicting @entity1 .

title: Assessment of jawbone trabecular bone structure amongst XXXX @entity0 by cone-beam computed tomography: the OSTEOSYR project.

answer: @entity2


abstract: OBJECTIVE: To assess the trabecular bone structure of jawbones and the dens (the odontoid process of the second cervical vertebra) amongst @entity2 and nonosteoporotic @entity0 using cone-beam computed tomography (CBCT). Analysis of the dens trabecular bone structure aimed to test the validity of CBCT in such analysis. METHODS: Thirty-eight @entity0 who went under dual-energy X-ray absorptiometry (DXA) examination were scanned by CBCT. Cuboids from different areas of jawbones and the dens were extracted from each scan. Trabecular thickness (Tb.Th), trabecular separation (Tb.S), bone volume fraction (BV/TV), specific bone surface (BS/TV) and connectivity density were calculated. Student's t-test, Pearson correlation, and logistic regression analysis were used to explore differences in these measures between groups. RESULTS: Jawbone-derived measures showed insignificant differences (P  >  0.05) between @entity2 , and weak correlations with femoral neck and lumbar vertebrae T-scores (r   <=  0.4). Dens-derived measures, however, resulted in the opposite (r  =  0.34-0.38 [P  value  =  0.02-0.036] and r  =  0.48-0.61 [P  value   <=  0.003]) and the highest accuracy of @entity1 prediction: 84.2% and 78.9% respectively. CONCLUSION: Trabecular bone structure of the mandible and maxilla is not affected in @entity1 as assessed by CBCT. Dens trabecular bone analysis revealed the opposite, so some trabecular bone measures may be assessed by CBCT, which may aid in predicting @entity1 .

title: Assessment of jawbone trabecular bone structure amongst @entity2 XXXX by cone-beam computed tomography: the OSTEOSYR project.

answer: @entity0


abstract: The aim of the experiments was to evaluate the influence of @entity0 kisspeptin on LH secretion of @entity5 ( @entity5 ) females during ovarian recrudescence and spawning season. For the experiments, @entity0 kisspeptin @entity6 (0.1 mg kg(-1) of body weight--b.w.), @entity2 analogue (Des Gly(10), D-Ala(6)) GnRH-A (20   g kg(-1) b.w.) and @entity1 antagonist ( @entity3 ) (5 mg kg(-1) b.w.) were used alone or in combinations. At 3, 6, 12, 24 hours after injection(s) blood samples were collected from all fish. LH levels were measured in plasma with the use of the ELISA method. @entity6 did not show any significant effects on spontaneous LH secretion in both tested seasons. At 12 hours sampling time (both stages of gonad maturity) a combination of tested compounds (GnRH-A+ @entity6 ) significantly increased LH release in comparison with the control. In the stage of gonad recrudescence @entity6 significantly increased LH secretion evoked by @entity3 at 24 hours. A combination of three components: @entity6 , GnRH-A, and @entity3 significantly decreased LH secretion in comparison to LH secretion evoked by @entity4 and @entity3 during stage of gonad recrudescence. These results suggest that kisspeptin is involved in seasonal control of reproduction in @entity5 . The possible interaction of kisspeptin and the dopaminergic system is also discussed.

title: Preliminary Results Concerning the Influence of @entity0 Kisspeptin on LH Secretion in XXXX ( @entity5 ) Females at the Stage of Ovarian Recrudescence and Spawning Season.

answer: @entity5


abstract: The aim of the experiments was to evaluate the influence of @entity0 kisspeptin on LH secretion of @entity5 ( @entity5 ) females during ovarian recrudescence and spawning season. For the experiments, @entity0 kisspeptin @entity6 (0.1 mg kg(-1) of body weight--b.w.), @entity2 analogue (Des Gly(10), D-Ala(6)) GnRH-A (20   g kg(-1) b.w.) and @entity1 antagonist ( @entity3 ) (5 mg kg(-1) b.w.) were used alone or in combinations. At 3, 6, 12, 24 hours after injection(s) blood samples were collected from all fish. LH levels were measured in plasma with the use of the ELISA method. @entity6 did not show any significant effects on spontaneous LH secretion in both tested seasons. At 12 hours sampling time (both stages of gonad maturity) a combination of tested compounds (GnRH-A+ @entity6 ) significantly increased LH release in comparison with the control. In the stage of gonad recrudescence @entity6 significantly increased LH secretion evoked by @entity3 at 24 hours. A combination of three components: @entity6 , GnRH-A, and @entity3 significantly decreased LH secretion in comparison to LH secretion evoked by @entity4 and @entity3 during stage of gonad recrudescence. These results suggest that kisspeptin is involved in seasonal control of reproduction in @entity5 . The possible interaction of kisspeptin and the dopaminergic system is also discussed.

title: Preliminary Results Concerning the Influence of @entity0 Kisspeptin on LH Secretion in @entity5 ( XXXX ) Females at the Stage of Ovarian Recrudescence and Spawning Season.

answer: @entity5


abstract: The aim of the experiments was to evaluate the influence of @entity0 kisspeptin on LH secretion of @entity5 ( @entity5 ) females during ovarian recrudescence and spawning season. For the experiments, @entity0 kisspeptin @entity6 (0.1 mg kg(-1) of body weight--b.w.), @entity2 analogue (Des Gly(10), D-Ala(6)) GnRH-A (20   g kg(-1) b.w.) and @entity1 antagonist ( @entity3 ) (5 mg kg(-1) b.w.) were used alone or in combinations. At 3, 6, 12, 24 hours after injection(s) blood samples were collected from all fish. LH levels were measured in plasma with the use of the ELISA method. @entity6 did not show any significant effects on spontaneous LH secretion in both tested seasons. At 12 hours sampling time (both stages of gonad maturity) a combination of tested compounds (GnRH-A+ @entity6 ) significantly increased LH release in comparison with the control. In the stage of gonad recrudescence @entity6 significantly increased LH secretion evoked by @entity3 at 24 hours. A combination of three components: @entity6 , GnRH-A, and @entity3 significantly decreased LH secretion in comparison to LH secretion evoked by @entity4 and @entity3 during stage of gonad recrudescence. These results suggest that kisspeptin is involved in seasonal control of reproduction in @entity5 . The possible interaction of kisspeptin and the dopaminergic system is also discussed.

title: Preliminary Results Concerning the Influence of XXXX Kisspeptin on LH Secretion in @entity5 ( @entity5 ) Females at the Stage of Ovarian Recrudescence and Spawning Season.

answer: @entity0


abstract: Kekul   first suggested a hexagonal structure for @entity1 in 1865. For over a half-century after, chemists struggled to reconcile proposed structures for @entity1 and other aromatic compounds with their resistance to chemical transformation and tendency to maintain the type during reaction. The combined structural and reactivity features of these compounds were eventually covered by the term ' @entity3 '. Kekul  , Bamberger and Thiele had each proposed a criterion for @entity3 ; all were either empirically contradicted or incapable of evaluation. In the 1930s, two rival quantum mechanical methods succeeded in establishing a physical basis for @entity3 . Using valence bond theory, Pauling attributed @entity1 's stability to its being a resonance hybrid of several Lewis structures. Calculating resonance energies was challenging but manipulating Lewis structures was not; that procedure provided qualitative insights into aromatic structure and reactivity. Resonance theory appealed especially to organic chemists and eclipsed H  ckel's contemporaneous molecular orbital approach, which remained relatively inaccessible. In the 1950s, however, simple rules derived from H  ckel's mathematics, combined with proton NMR data, provided seemingly universal criteria for @entity3 . In the event, post-1950 discoveries of non-organic, three-dimensional compounds such as @entity0 and the @entity2 that exhibit aromatic properties led chemists to doubt the utility and universality of ' @entity3 ' as a concept. A recent consensus maintains that @entity3 is a multi-variable phenomenon that cannot be reduced to a strict definition, a property it shares with other core chemical concepts such as 'acidity' and 'reactivity'.

title: XXXX and Beyond: Pursuing the Core of Aromaticity.

answer: @entity1


abstract: AIMS: To review retrospectively 16 cases of @entity5 ( @entity5 ) with emphasis on their clinical and pathological characteristics, treatment and possible prognostic factors. METHODS AND RESULTS: All eligible cases were searched and acquired from archives of the pathology departments of two hospitals in Shanghai, The Fifth @entity0 's Hospital of Shanghai, Fudan University, and the Shanghai Cancer Center, Fudan University, China. The @entity0 ranged in age from 19 to 77 years, and 5 @entity0 were below 50 years of age. Microscopically, the @entity1 were mostly composed of large, round or polygonal epithelioid cells that were predominantly arranged in solid sheets or nests. The @entity1 cells had basophilic or eosinophilic cytoplasm, vesicular nuclei, and prominent nucleoli. Mitotic figures including abnormal mitoses were frequently encountered. In all 16 cases in our series, immunohistochemical studies showed positivity for @entity3 , and partial positivity for @entity6 , @entity4 and factor VIII-related antigen. Of the 14 @entity0 available for follow-up, 3 @entity0 were alive with disease, 9 @entity0 died as a result of the @entity1 , 1 died of local @entity2 , and one died of unknown etiology. The median survival was 17.1 months. CONCLUSIONS: EA is highly aggressive and carries a very poor prognosis. Therefore, the clinical recognition and correct diagnosis of EA are essential.

title: XXXX : a clinicopathological study of 16 Chinese cases.

answer: @entity5


abstract: UNASSIGNED: Bronchogenic cysts (BCs) are @entity1 that originate from remnants of the primitive foregut. Intraspinal BCs, especially those of the conus medullaris are rare with only one case reported until now. To date, a @entity4 with spinal cord tethering has not been previously reported. We reviewed the clinical course of a 44-year-old @entity0 , who presented with @entity3 and leg weaknesss as well as sphincter disturbance. Magnetic resonance imaging showed an intradural oval mass located at the conus medullaris. A tethered cord was also observed, as well as a @entity5 . The mass was totally removed after an L3-L4 laminectomy without detethering during operation. Pathologic examination confirmed the diagnosis of @entity4 . By six months after treatment, the @entity0 had experienced nearly complete recovery. The review of literature indicated that detethering was performed in most reported cases of @entity2 with spinal cord tethering, and one of six @entity0 was diagnosed with a postoperative recurrence. The co-existence of @entity4 and a tethered spinal cord would imply associated developmental errors in embryogenesis. It is worth noting that whether detethering is necessary after the cyst removal.

title: XXXX with spinal cord tethering: a case report and review of the literature.

answer: @entity4


abstract: BACKGROUND: @entity2 is a @entity1 . Over the years, different approaches have been proposed to approach this heterogeneity by categorizing symptom patterns. The study aimed to compare positive/negative and system-specific approaches to subtyping. METHODS: We used the Positive and Negative Syndrome Scale (PANSS) and @entity3 ( @entity3 ), which consists of subscales for three domains (language, affect and motor behavior) that are hypothesized to be related to specific brain circuits, to assess cross-sectional psychopathological characteristics in a sample of 100 inpatients with @entity2 spectrum disorders. We then categorized @entity0 into positive/negative and system-specific subgroups to allow comparisons of the two approaches. RESULTS: The analyses revealed correlations between the PANSS positive subscore and the @entity3 affective subscore (r=.446, p<.001) and between the PANSS negative subscore and the @entity3 motor behavior subscore (r=.227, p=.023). As regards the positive and negative subtype, more @entity0 were classified as positive in the language-dominant subtype (30.3%) and affect-dominant subtype (30.3%), whereas more were classified as negative in the motor behavior-dominant subtype (44.4%). However, most @entity0 met the criteria for the mixed subtype. CONCLUSIONS: The results suggest that the positive/negative and system-specific approaches can be regarded as complementary. Future studies should examine both approaches in a longitudinal assessment of psychopathological symptoms and link them with qualitative-phenomenological approaches.

title: Subtyping XXXX : A comparison of positive/negative and system-specific approaches.

answer: @entity2


abstract: BACKGROUND: @entity3 ( @entity3 ) is one of the less prevalent @entity3 . The purpose of this study was to explore the clinicopathological characteristics and results of the operation of @entity3 following distal gastrectomy. In particular, we examined factors related to prognosis. METHODS: Between January 1970 and December 2012, 122 @entity0 with @entity3 following distal gastrectomy underwent further surgery and were analyzed retrospectively. RESULTS: Initial @entity5 included benign (49 @entity0 , 40.2  %) and @entity2 (73 @entity0 , 59.8  %). Reconstructions by initial surgery included Billroth I (80 @entity0 , 65.6  %) and @entity4 (42 @entity0 , 34.4  %). @entity2 were located at anastomotic (44 @entity0 , 36.1  %) and nonanastomotic sites (78 @entity0 , 63.9  %). There were 59 @entity0 (48.4  %) classified with pathological (p) stage I, 19 as p stage II (15.6  %), 22 as p stage III (18.0  %), and 22 (18.0  %) as p stage IV. A total of 100 @entity0 (82.0  %) underwent curative resection, and 22 underwent noncurative resection. The number of cases of postoperative morbidity, 90-day mortality, and adjuvant chemotherapy were 23 (18.9  %), 3 (2.5  %), and 20 (16.4  %), respectively. Univariate and multivariate analyses were performed to identify the prognostic factors of @entity3 . Multivariate analysis revealed historical periods, pathological @entity1 , curative resection, and postoperative morbidity to be independent prognostic factors. CONCLUSIONS: The prognosis of @entity0 with @entity3 can be improved by aggressively performing curative resection without causing complications.

title: Surgical Resection of Remnant XXXX Following Distal Gastrectomy: A Retrospective Clinicopathological Study.

answer: @entity3


abstract: PURPOSE: To investigate the association between @entity3 ( @entity3 ) and @entity2 ( @entity2 ) assessed by coronary artery @entity1 -scoring dual-source computed tomography (DSCT). MATERIALS AND METHODS: We retrospectively analyzed 143 consecutive @entity0 who underwent coronary artery @entity1 -scoring during coronary DSCT angiography. 57 @entity0 had findings of @entity3 on @entity1 -scoring scans. @entity3 volume (ARCV) and Agatston coronary artery @entity1 score (CACS) were calculated. Chi-square test was used to assess differences of categorical variables between @entity0 with and without @entity3 . Statistical significances between both groups were assessed with the independent-Sample t test. RESULTS: Compared with @entity0 without @entity3 (n=86), @entity0 with @entity3 (n=57) showed a significantly higher presence of @entity2 (87.7% vs. 24.4%; P<0.001), and a higher mean CACS (700.6  941.2 vs. 256.4  724.3; P=0.009) in @entity0 with @entity2 . @entity0 with a calculated ARCV >40mm(3) (n=32) showed significantly higher rates of severe @entity2 (56.3% vs. 24.0%; P=0.014) compared with @entity0 with an ARCV<40mm(3) (n=25). Compared with @entity0 without @entity2 (n=42), @entity0 with @entity2 (n=101) showed a significantly higher presence of @entity3 (83.3% vs. 50.5%; P<0.001) and a higher mean ARCV (95.4  116.2mm(3) vs. 29.7  33.0 mm(3); P=0.003). Severe @entity2 (n=24) correlated with an increased mean ARCV (122.3  148.8mm(3)) compared to @entity0 with minimal to moderate @entity2 (n=33, mean ARCV: 61.9  64.8mm(3); P<0.05). CONCLUSIONS: The extent of @entity3 is directly associated with the presence and degree of @entity2 on @entity1 -scoring scans during coronary DSCT angiography.

title: Association of XXXX severity with the extent of @entity2 assessed by @entity1 -scoring dual-source computed tomography.

answer: @entity3


abstract: PURPOSE: To investigate the association between @entity3 ( @entity3 ) and @entity2 ( @entity2 ) assessed by coronary artery @entity1 -scoring dual-source computed tomography (DSCT). MATERIALS AND METHODS: We retrospectively analyzed 143 consecutive @entity0 who underwent coronary artery @entity1 -scoring during coronary DSCT angiography. 57 @entity0 had findings of @entity3 on @entity1 -scoring scans. @entity3 volume (ARCV) and Agatston coronary artery @entity1 score (CACS) were calculated. Chi-square test was used to assess differences of categorical variables between @entity0 with and without @entity3 . Statistical significances between both groups were assessed with the independent-Sample t test. RESULTS: Compared with @entity0 without @entity3 (n=86), @entity0 with @entity3 (n=57) showed a significantly higher presence of @entity2 (87.7% vs. 24.4%; P<0.001), and a higher mean CACS (700.6  941.2 vs. 256.4  724.3; P=0.009) in @entity0 with @entity2 . @entity0 with a calculated ARCV >40mm(3) (n=32) showed significantly higher rates of severe @entity2 (56.3% vs. 24.0%; P=0.014) compared with @entity0 with an ARCV<40mm(3) (n=25). Compared with @entity0 without @entity2 (n=42), @entity0 with @entity2 (n=101) showed a significantly higher presence of @entity3 (83.3% vs. 50.5%; P<0.001) and a higher mean ARCV (95.4  116.2mm(3) vs. 29.7  33.0 mm(3); P=0.003). Severe @entity2 (n=24) correlated with an increased mean ARCV (122.3  148.8mm(3)) compared to @entity0 with minimal to moderate @entity2 (n=33, mean ARCV: 61.9  64.8mm(3); P<0.05). CONCLUSIONS: The extent of @entity3 is directly associated with the presence and degree of @entity2 on @entity1 -scoring scans during coronary DSCT angiography.

title: Association of @entity3 severity with the extent of @entity2 assessed by XXXX -scoring dual-source computed tomography.

answer: @entity1


abstract: PURPOSE: To investigate the association between @entity3 ( @entity3 ) and @entity2 ( @entity2 ) assessed by coronary artery @entity1 -scoring dual-source computed tomography (DSCT). MATERIALS AND METHODS: We retrospectively analyzed 143 consecutive @entity0 who underwent coronary artery @entity1 -scoring during coronary DSCT angiography. 57 @entity0 had findings of @entity3 on @entity1 -scoring scans. @entity3 volume (ARCV) and Agatston coronary artery @entity1 score (CACS) were calculated. Chi-square test was used to assess differences of categorical variables between @entity0 with and without @entity3 . Statistical significances between both groups were assessed with the independent-Sample t test. RESULTS: Compared with @entity0 without @entity3 (n=86), @entity0 with @entity3 (n=57) showed a significantly higher presence of @entity2 (87.7% vs. 24.4%; P<0.001), and a higher mean CACS (700.6  941.2 vs. 256.4  724.3; P=0.009) in @entity0 with @entity2 . @entity0 with a calculated ARCV >40mm(3) (n=32) showed significantly higher rates of severe @entity2 (56.3% vs. 24.0%; P=0.014) compared with @entity0 with an ARCV<40mm(3) (n=25). Compared with @entity0 without @entity2 (n=42), @entity0 with @entity2 (n=101) showed a significantly higher presence of @entity3 (83.3% vs. 50.5%; P<0.001) and a higher mean ARCV (95.4  116.2mm(3) vs. 29.7  33.0 mm(3); P=0.003). Severe @entity2 (n=24) correlated with an increased mean ARCV (122.3  148.8mm(3)) compared to @entity0 with minimal to moderate @entity2 (n=33, mean ARCV: 61.9  64.8mm(3); P<0.05). CONCLUSIONS: The extent of @entity3 is directly associated with the presence and degree of @entity2 on @entity1 -scoring scans during coronary DSCT angiography.

title: Association of @entity3 severity with the extent of XXXX assessed by @entity1 -scoring dual-source computed tomography.

answer: @entity2


abstract: UNASSIGNED: @entity0 telomeres are G-rich tandem repeats that assume G-quadruplex structures at the ends of chromosomes. Stabilization of telomeric G-quadruplex represents a significant drug target for inhibiting the telomerase activity that is required in ~85% of @entity1 . Metal ions have been revealed as important stabilizers to DNA G-quadruplexes, but their binding process with @entity0 telomeric G-quadruplex remains unclear. In this report, we show that @entity2 traverses into the G-tetrads center of two G-tetrad layers through the half-capped top pathway constructed by the two edge-wise loop bases. The binding is mediated by the electrostatic interactions between @entity2 and the nearby bases of G-tetrads. However, direct traverse of @entity2 into the interior of G-quadruplex is negatively regulated by the steric hindrance of water molecules. Once @entity2 enters the G-quadruplex, stabilization of the in-plane or sandwiched conformation of the telomeric G-quadruplex- @entity2 complex is maintained by surrounding water molecules. These findings provide insights into the atomic interactions between @entity2 and telomere G-tetrads for targeted drug design. This article is protected by copyright. All rights reserved.

title: Characterization of potassium binding with XXXX telomeres.

answer: @entity0


abstract: BACKGROUND: Ixeris dentata Nakai has been used for the treatment of mithridatism, calculous, indigestion, @entity5 , @entity6 , and @entity1 in Korea, China, and Japan. However, the effect of a water extract of Ixeris dentata (ID) and its molecular mechanism on @entity3 has not been elucidated. In this study, we attempted to evaluate the effects of ID and its major compound @entity11 on @entity3 in vivo and in vitro. METHODS: ID was applied to @entity12 (DNFB)-induced @entity8 ( @entity8 )-like @entity7 @entity2 and immune cell infiltration, cytokine production, and the activation of mitogen-activated protein kinases (MAPKs) were investigated. Moreover, the effect of ID on compound 48/80-induced anaphylactic shock was investigated in a @entity2 model. The @entity0 keratinocyte cell line (HaCaT cells) and @entity0 mast cells (HMC-1) were treated with ID or @entity11 to investigate the effects on the production of chemokines and proinflammatory cytokines and on the activation of MAPKs. RESULTS: ID inhibited the serum levels of IgE and interleukin (IL)-1b in DNFB-induced @entity8 -like @entity7 @entity2 models and suppressed anaphylactic shock in the @entity2 models. ID and @entity11 inhibited the production of chemokines and adhesion molecules in HaCaT cells. In addition, ID reduced the release of @entity1 @entity4 factor-a and @entity10 via the inhibition of MAPKs phosphorylation in HMC-1 cells. CONCLUSIONS: These results suggest that ID is a potential therapeutic agent for allergic inflammatory diseases, including @entity9 .

title: Effects of Ixeris dentata water extract and XXXX on @entity3 in vivo and in vitro.

answer: @entity11


abstract: BACKGROUND: Ixeris dentata Nakai has been used for the treatment of mithridatism, calculous, indigestion, @entity5 , @entity6 , and @entity1 in Korea, China, and Japan. However, the effect of a water extract of Ixeris dentata (ID) and its molecular mechanism on @entity3 has not been elucidated. In this study, we attempted to evaluate the effects of ID and its major compound @entity11 on @entity3 in vivo and in vitro. METHODS: ID was applied to @entity12 (DNFB)-induced @entity8 ( @entity8 )-like @entity7 @entity2 and immune cell infiltration, cytokine production, and the activation of mitogen-activated protein kinases (MAPKs) were investigated. Moreover, the effect of ID on compound 48/80-induced anaphylactic shock was investigated in a @entity2 model. The @entity0 keratinocyte cell line (HaCaT cells) and @entity0 mast cells (HMC-1) were treated with ID or @entity11 to investigate the effects on the production of chemokines and proinflammatory cytokines and on the activation of MAPKs. RESULTS: ID inhibited the serum levels of IgE and interleukin (IL)-1b in DNFB-induced @entity8 -like @entity7 @entity2 models and suppressed anaphylactic shock in the @entity2 models. ID and @entity11 inhibited the production of chemokines and adhesion molecules in HaCaT cells. In addition, ID reduced the release of @entity1 @entity4 factor-a and @entity10 via the inhibition of MAPKs phosphorylation in HMC-1 cells. CONCLUSIONS: These results suggest that ID is a potential therapeutic agent for allergic inflammatory diseases, including @entity9 .

title: Effects of Ixeris dentata water extract and @entity11 on XXXX in vivo and in vitro.

answer: @entity3


abstract: BACKGROUND: Defining the threshold for therapeutic and surgical intervention in @entity0 with @entity1 presents a considerable challenge given the lack of clear, evidence-based data. Little is known about the patterns of practice and referral criteria of optometrists within Australia. METHODS: All members of the NSW branch of Optometrist Association Australia were invited to complete an online survey in January 2013. This survey was designed to elicit practice information regarding the evaluation and therapeutic treatment of @entity0 with @entity1 in the optometric setting. RESULTS: Responses were received from 71 optometrists, of whom 65.2 per cent had 15 years or greater experience as an optometrist. Many (35.4 per cent) responded that they prescribed soft contact lenses daily. This percentage dropped to 9.2 per cent for rigid gas-permeable lenses (RGP), although 47.7 per cent said they would prescribe RGP lenses at least once per month. The main barriers to prescribing were experience with fitting RGP lenses, time and low market demand. In terms of @entity0 referral to an ophthalmologist, the results were variable, with 34.4 per cent stating that they would refer on progression of corneal signs, 23.4 per cent suggesting no set time and 7.8 per cent would refer on initial diagnosis. Many optometrists (62.9 per cent) would refer a @entity0 for possible surgery, when visual acuity dropped to between 6/9 and 6/12. The size or location of the practice was not associated with the number of newly diagnosed cases of @entity1 . Optometrists with greater experience were more likely to prescribe RGP lenses and co-manage @entity0 with ophthalmologists. Ownership of a corneal topographic unit suggested an increased likelihood of prescribing RGP lenses but did not appear to alter referral patterns. CONCLUSION: Optometrists have an integral role in the diagnosis and management of @entity0 with @entity1 . Our survey provides a basic snapshot of current, local practice. Additionally, ophthalmology should continue to work with optometry to develop guidelines for referral and co-management to optimise future outcomes for our @entity0 .

title: Therapeutic treatment of XXXX : a survey of local optometric practice criteria.

answer: @entity1


abstract: BACKGROUND: Functional and morphological @entity1 have been widely described in @entity6 for decades. Nevertheless few studies have assessed renal function pre- and during treatment after the advent of @entity8 ( @entity8 ). METHODS: This is a prospective study involving 189 consecutive @entity0 , with all forms of @entity6 (Ridley-Jopling scale). Laboratory (serum @entity5 and @entity4 , estimated GFR, urinalysis, microalbuminuria, urinary @entity9 ) and clinical features of @entity1 were evaluated previously and after onset (3 and 8 months later) of @entity8 . RESULTS: One hundred and eighty-nine @entity0 (M 1.8: F 1; mean age 44        16 years) were included just after diagnosis of @entity6 and before the introduction of @entity8 . Mean time until manifestation of symptoms and/or signs of @entity6 was 29        56 months (25 days-480 months). Microhematuria and microalbuminuria were detected in 7.5% and 9.6% of the cases, respectively. Elevated serum @entity4 was detected in 34% pre- @entity8 ; this was statistically more frequent in males, @entity2 and frequent users of non-steroidal anti-inflammatory drugs (NSAID), as well as in @entity0 with @entity7 , 45.5% by the time of diagnosis, 18% after 3 months and 9% after 8 months of @entity8 (p   =   0.039). CONCLUSIONS: Our results suggest that functional @entity1 in @entity6 are currently mild and predominantly of glomerular origin, in opposition to the severe involvement described in the past. This improved outcome of @entity1 secondary to @entity6 is possibly due to the advent of @entity8 and effective treatment of episodes of reaction, leading to shorter periods of active @entity3 .

title: It is time to review concepts on renal involvement in XXXX : pre- and post-treatment evaluation of 189 @entity0 .

answer: @entity6


abstract: BACKGROUND: Functional and morphological @entity1 have been widely described in @entity6 for decades. Nevertheless few studies have assessed renal function pre- and during treatment after the advent of @entity8 ( @entity8 ). METHODS: This is a prospective study involving 189 consecutive @entity0 , with all forms of @entity6 (Ridley-Jopling scale). Laboratory (serum @entity5 and @entity4 , estimated GFR, urinalysis, microalbuminuria, urinary @entity9 ) and clinical features of @entity1 were evaluated previously and after onset (3 and 8 months later) of @entity8 . RESULTS: One hundred and eighty-nine @entity0 (M 1.8: F 1; mean age 44        16 years) were included just after diagnosis of @entity6 and before the introduction of @entity8 . Mean time until manifestation of symptoms and/or signs of @entity6 was 29        56 months (25 days-480 months). Microhematuria and microalbuminuria were detected in 7.5% and 9.6% of the cases, respectively. Elevated serum @entity4 was detected in 34% pre- @entity8 ; this was statistically more frequent in males, @entity2 and frequent users of non-steroidal anti-inflammatory drugs (NSAID), as well as in @entity0 with @entity7 , 45.5% by the time of diagnosis, 18% after 3 months and 9% after 8 months of @entity8 (p   =   0.039). CONCLUSIONS: Our results suggest that functional @entity1 in @entity6 are currently mild and predominantly of glomerular origin, in opposition to the severe involvement described in the past. This improved outcome of @entity1 secondary to @entity6 is possibly due to the advent of @entity8 and effective treatment of episodes of reaction, leading to shorter periods of active @entity3 .

title: It is time to review concepts on renal involvement in @entity6 : pre- and post-treatment evaluation of 189 XXXX .

answer: @entity0